195 related articles for article (PubMed ID: 16382111)
1. Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia.
Noronha V; Fynan TM; Duffy T
J Clin Oncol; 2006 Jan; 24(1):e3. PubMed ID: 16382111
[No Abstract] [Full Text] [Related]
2. Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström's macroglobulinemia.
Alfaraj WA; Cachia D; Tummala S; Thomas SK; Manasanch EE
Ann Hematol; 2016 Jan; 95(2):347-8. PubMed ID: 26432713
[No Abstract] [Full Text] [Related]
3. Case of mononeuritis multiplex onset with rituximab therapy for Waldenström's macroglobulinemia.
Mauermann ML; Ryan ML; Moon JS; Klein CJ
J Neurol Sci; 2007 Sep; 260(1-2):240-3. PubMed ID: 17537458
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma followed by Waldenström's macroglobulinemia: a case report.
Hasegawa K; Kubota K; Hirai H; Imai Y; Midorikawa Y; Makuuchi M
Hepatogastroenterology; 2000; 47(33):842-5. PubMed ID: 10919044
[TBL] [Abstract][Full Text] [Related]
5. Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab.
Buda-Okreglak EM; Drabick JJ; Delaney NR
Ann Hematol; 2004 Feb; 83(2):117-9. PubMed ID: 14513285
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Chu L; Musto P; Baron AD; Nunnink JC; Kash JJ; Terjanian TO; Hyman PM; Nawfel EL; Sharon DJ; Munshi NC; Anderson KC
Clin Cancer Res; 2009 Jan; 15(1):355-60. PubMed ID: 19118065
[TBL] [Abstract][Full Text] [Related]
7. [Effective treatment with rituximab in two patients with Waldenström macroglobulinemia].
Yoshimi A; Arai S; Iijima K; Iki S; Usuki K; Urabe A
Rinsho Ketsueki; 2005 Oct; 46(10):1109-13. PubMed ID: 16440772
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin M 'Flare' after rituximab-associated acute tubular necrosis in Waldenström's macroglobulinemia.
Izzedine H; Bourry E; Amrouche L; Brocheriou I; Uzunov M; Capron F; Leblond V; Deray G
Int J Hematol; 2009 Mar; 89(2):218-222. PubMed ID: 19156501
[TBL] [Abstract][Full Text] [Related]
9. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
[TBL] [Abstract][Full Text] [Related]
10. Waldenström's macroglobulinemia and bortezomib.
Leblond V
Haematologica; 2005 Dec; 90(12):1589A. PubMed ID: 16330427
[No Abstract] [Full Text] [Related]
11. Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy.
Liberato B; Riethmuller A; Comenzo RL; Lis E; Raizer JJ
J Neurooncol; 2003 Jun; 63(2):207-11. PubMed ID: 12825826
[TBL] [Abstract][Full Text] [Related]
12. An unusual reoccurrence of Waldenstrom's macroglobulinemia as pleural effusions that had a discordant response with treatment.
Amin CJ; Rabinowitz I
Clin Lab Haematol; 2005 Jun; 27(3):200-2. PubMed ID: 15938727
[TBL] [Abstract][Full Text] [Related]
13. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study.
Ghobrial IM; Fonseca R; Greipp PR; Blood E; Rue M; Vesole DH; Gertz MA;
Cancer; 2004 Dec; 101(11):2593-8. PubMed ID: 15493038
[TBL] [Abstract][Full Text] [Related]
14. IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy.
Campagnolo M; Zambello R; Nobile-Orazio E; Benedetti L; Marfia GA; Riva N; Castellani F; Bianco M; Salvalaggio A; Garnero M; Ruiz M; Mataluni G; Fazio R; Ermani M; Briani C
J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1094-1097. PubMed ID: 28501820
[No Abstract] [Full Text] [Related]
15. Nervous system dysfunction in Waldenström's macroglobulinemia: response to treatment.
Rudnicki SA; Harik SI; Dhodapkar M; Barlogie B; Eidelberg D
Neurology; 1998 Oct; 51(4):1210-3. PubMed ID: 9781565
[TBL] [Abstract][Full Text] [Related]
16. The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens.
Dimopoulos MA; Kastritis E; Delimpassi S; Zomas A; Kyrtsonis MC; Zervas K
Haematologica; 2008 Sep; 93(9):1420-2. PubMed ID: 18641029
[No Abstract] [Full Text] [Related]
17. Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-mag neuropathy after treatment with rituximab.
Gironi M; Saresella M; Ceresa L; Calvo M; Ferrante P; Merli F; Nemni R
Haematologica; 2006 Jun; 91(6 Suppl):ECR17. PubMed ID: 16785123
[No Abstract] [Full Text] [Related]
18. Development of nasal skin necrosis associated with rituximab treatment for Waldenström's macroglobulinemia and subsequent spontaneous resolution.
Pearlman AN; Fechner FP; Constantinides M
Ear Nose Throat J; 2006 Jul; 85(7):431-3. PubMed ID: 16909812
[TBL] [Abstract][Full Text] [Related]
19. [Peripheral neuropathy in Waldenstrom's macroglobulinemia. Antibody activity of monoclonal immunoglobulin M directed against vimentin].
Dellagi K; Chedru F; Clauvel JP; Brouet JC
Presse Med; 1984 May; 13(19):1199-201. PubMed ID: 6326084
[TBL] [Abstract][Full Text] [Related]
20. Advances in the treatment of Waldenström's macroglobulinemia.
Johnson SA
Expert Rev Anticancer Ther; 2006 Mar; 6(3):329-34. PubMed ID: 16503850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
